Chronic Lymphocytic Leukemia Patient Management Simulator

Recent advances in understanding the biology of chronic lymphocytic leukemia (CLL) have resulted in the development of novel therapies targeting key signaling pathways involved in the pathogenesis of this disease. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma have been updated to reflect these changes. It is important for clinicians to be aware of these updates so that they can develop individualized treatment plans for newly diagnosed, relapsed, or refractory CLL based on the patient and disease characteristics (age, comorbidities, disease stage, and mutation status), toxicity profile of the agent, and prior treatment.

The goal of this project is to ensure that physicians, nurses, and other relevant healthcare professionals have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with CLL. This activity will help reach that goal by increasing clinicians’ confidence in applying the latest evidence to practice.

Target Audience

This activity is designed to meet the educational needs of the interprofessional oncology care team members who manage the treatment of CLL patients, including medical oncologists, hematologists, oncology nurses, and pharmacists.

Learning Objectives

Following this activity, participants should be able to:

  • Review the current treatment options and unique challenges associated with the management of patients with newly diagnosed or relapsed/refractory CLL.
  • Develop individualized treatment plans for patients with newly diagnosed CLL based on the patient’s functional status and the presence of cytogenetic abnormalities.
  • Select the appropriate treatment option for patients with relapsed/refractory CLL based on prior treatment, functional status, and the presence of cytogenetic abnormalities.
Additional information

This activity is supported by educational grants from AstraZeneca and Verastem Oncology.
This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.
This activity is supported by an independent medical education grant from Pharmacyclics LLC and Janssen.

Course summary
Course opens: 
Course expires: 

William Wierda, MD – Dr. Wierda is the Executive Medical Director, Center Medical Director of the Department of Leukemia, Section Chief - Chronic Lymphocytic Leukemia, D.B. Lane Cancer Research Distinguished Professor and Professor- Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX.

Jennifer R. Brown, MD, PhD – Dr. Brown is the Director of the CLL Center at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.


NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers 
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses the following relevant financial relationships:

Jennifer R. Brown, MD, PhD
AbbVie, Inc.: Consulting Fee
Acerta Pharma: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee
Catapult Therapeutics: Consulting Fee
Dynamo Therapeutics: Consulting Fee
Gilead Sciences, Inc.: Grant/Research Support
Invectys (Data Safety Committee, Non-financial): Other financial benefit
Janssen Pharmaceutica Products, LP: Honoraria
Juno Therapeutics, Inc./Celgene Corporation: Consulting Fee
Kite Pharma: Consulting Fee
Loxo Oncology, Inc.: Grant/Research Support
MorphoSys AG: Other financial benefit
Novartis Pharmaceuticals Corporation: Consulting Fee
Octapharma: Consulting Fee
Pharmacyclics: Consulting Fee
Sun Pharmaceutical Industries Ltd.: Honoraria
Sunesis Pharmaceuticals, Inc.: Consulting Fee
Teva Pharmaceutical Industries Ltd: Honoraria
TG Therapeutics: Consulting Fee
Verastem, Inc.: Grant/Research Support; Consulting Fee

William C. Wierda, MD, PhD
AbbVie, Inc.: Grant/Research Support
Acerta Pharma: Grant/Research Support
Cyclacel Pharmaceuticals, Inc.: Grant/Research Support
Genentech: Grant/Research Support
Genzyme Corporation: Consulting Fee
Gilead Sciences, Inc.: Grant/Research Support
GlaxoSmithKline/Novartis Pharmaceuticals Corporation: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support
Juno Therapeutics, Inc.: Grant/Research Support
Karyopharm Therapeutics: Grant/Research Support
Kite Pharma: Grant/Research Support
Loxo Oncology, Inc.: Grant/Research Support
Oncternal Therapeutics, Inc.: Grant/Research Support
Pharmacyclics: Grant/Research Support
Sunesis Pharmaceuticals, Inc.: Grant/Research Support
Xencor, Inc.: Grant/Research Support

NCCN Staff Disclosures 
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Heather Matt; Lisa Perfidio, MS

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Hema Sundar, PhD

The Syandus, Inc staff listed below discloses the following relevant financial relationships: 
Douglas Seifert, PhD
Amgen: Technology services unrelated to Amgen medical product information.
Merck: Technology services unrelated to Merck medical product information.

The Syandus, Inc staff listed below disclose no relevant financial relationships:
Jill M. Herr, MD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 2 contact hours.

NCCN designates this knowledge-based continuing education activity for 2 contact hours (0.2 CEUs) of continuing education credit. UAN: JA4008196-9999-20-040-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. Approval is valid until 6/7/2021. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Pathology Maintenance of Certification

This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Maintenance of Certification program.  Participants may earn up to 2 Lifelong Learning (Part II) credits.

Aggregated participant data will be shared with the commercial supporters of this activity.


Please login or register to take this course.

Method of Participation to Earn Credit

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. Launch the simulation by clicking the Take Course button. (Please note that you will be directed to another site for the simulation.) Interact appropriately to satisfy each objective to unlock the next objective. The simulation will track your progress until all objectives and assessment components are complete. If you exit, the simulation will save your progress so that you can return to finish at a later time.     
  3. As you successfully complete more scenarios, you will qualify for increasing levels of CE credit (ranging from 0.5 to 2.0 credits). Click or tap “Credit” to determine your CE credit status and receive credit. Upon successful completion of the post-test and evaluation, you will receive a certificate of credit immediately via email (if connected to the internet). If you wish to complete more of the simulation and receive more CE credit, simply request additional credit.


For further information about this activity, contact; for technical support for this activity, contact